|Bid||0.1350 x 0|
|Ask||0.1450 x 0|
|Day's range||0.1350 - 0.1450|
|52-week range||0.0690 - 0.2000|
|Beta (5Y monthly)||0.81|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
AusCann Group Holdings Ltd (ASX:AC8), an Australian based pharmaceutical company focused on the development, production and distribution of cannabinoid-based medicines within Australia and internationally, is pleased to announce that it has entered into a scheme implementation deed (SID) with CannPal Animal Therapeutics Limited.
The CEO of CannPal Animal Therapeutics Limited (ASX:CP1) is Layton Mills, and this article examines the executive's...
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...